BPC-157 10MG

Description

BPC-157 10mg research peptide — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

BPC-157 is a fifteen-residue synthetic peptide (GEPPPGKPADDAGLV) taken from a larger protein that a Zagreb group isolated from gastric juice and named “body protection compound” in 1993; the same year they tested the fragment against bromocriptine, amantadine and somatostatin in rat liver-injury models^{[1, 2]}. Its literature is almost entirely rodent and cell-culture work, and a 2026 review counts no approved formulation and no completed Phase II trial^[6]. This listing is one sealed vial of lyophilized powder at a 10mg labelled amount, for laboratory research only.

Full research overview, study table & references → BPC-157 Canada (part of our BPC-157 Canada range: 5mg, 10mg and blends)

Identity at a glance

Batch documentation

A batch-specific COA for this strength has not been posted yet — see the COA library (/coa/). The 5mg vial carries a posted Janoshik report; that document covers the 5 mg batch only and is not evidence for this 10mg listing. When a report for a 10mg lot is issued it will be embedded here and filed in the library.

What researchers have looked at

• Rat liver injury (1993): given intragastrically or intraperitoneally, the peptide prevented necrosis or fatty change after bile-duct plus hepatic-artery ligation, restraint stress and carbon tetrachloride, where the three reference drugs had little or no effect^[2].
• Blood vessels (2017): more vessel formation in the chick chorioallantoic membrane and in endothelial tube assays, faster blood-flow recovery in rat hind-limb ischaemia, and VEGFR2 activation in cultured endothelial cells^[3].
• Rat Achilles repair (2026, 32 rats): BPC-157 alone gave numerically higher load to failure and lower histology scores than controls without reaching statistical significance for total scores, whereas TB-500 did; the combination lowered the Movin score^[4].
• Limits: a 2025 systematic review found the evidence preclinical, notes the compound is not FDA-approved and is banned in professional sport^[5]; the 2026 biopharmaceutical review records no validated dosing regimen and no completed Phase II trial^[6].

Those are animal and in-vitro findings about the compound, reported as literature. They are not properties of this vial and no benefit is claimed for it.

Storage and handling

• Sealed vial at −20 °C for long-term storage (the site states up to 24 months as dry powder); cool, dry and dark if held briefly; no repeated freeze–thaw.
• Solutions are less stable than powder; prepare only what an experiment needs. Reconstitution and handling protocols belong to the researcher and are not described on this site.

Also listed: BPC-157 5MG (posted COA) · BPC-157/TB-500 10MG · BPC-157/TB-500 20MG. Ships from inside Canada by Canada Post; the shipping policy has dispatch cut-off, delivery times and the free-shipping threshold. The rest of the range is on the page where you can buy peptides online in Canada.

Related reading: BPC-157 vs GHK-Cu: Two Repair Peptides, Two Different Mechanisms

Frequently asked questions

Can I buy BPC-157 10mg in Canada?

Yes. Shop Peptides Online stocks the 10mg vial as research-grade lyophilized BPC-157 and ships it from inside Canada by Canada Post, so there is no customs step. It is sold for laboratory research only; BPC-157 has no approved formulation anywhere (PMID 42198317).

Is there a COA for BPC-157 10mg?

Not yet for this strength. A batch-specific report for a 10 mg lot has not been posted; the report in the COA library covers the 5 mg batch only and does not apply to this listing. When a 10 mg report is issued it will be embedded on this page.

How should BPC-157 be stored?

Frozen at −20 °C in the sealed vial for long-term storage (the site states stability up to 24 months as lyophilized powder); cool, dry and dark for short periods; avoid freeze–thaw cycling. Reconstituted solutions are less stable than the powder.

Is BPC-157 for human use?

No. This vial is research-grade material for laboratory use only, not for human or animal consumption. BPC-157 is not approved by Health Canada, the FDA or the EMA, a 2025 systematic review found the evidence to be preclinical with the compound banned in professional sport (PMID 40756949), and Shop Peptides Online provides no dosing or administration guidance.

References

1. Sikirić P, Petek M et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. PMID 8298609
2. Sikiric P, Seiwerth S et al. (1993). Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci. PMID 7901724
3. Hsieh MJ, Liu HT et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). PMID 27847966
4. Biçer O, Adanir O et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. PMID 42542926
5. Vasireddi N, Hahamyan H et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. PMID 40756949
6. Mateescu DM, Gavrilescu DM et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. PMID 42198317

For laboratory research use only. Not for human or animal consumption. This description identifies the material and summarises published preclinical literature on the compound; it makes no claim of efficacy or safety for the material sold.